San Diego-based Oncternal Therapeutics is closing shop. To oversee the wind-down process, the company will retain only one employee: Craig Jalbert, a principal of the accounting firm Verdolino & Lowey, P.C. He will act as Oncternal’s president, CEO, treasurer, secretary and sole member of its board of directors. All remaining executives, directors and employees of Oncternal have resigned, though it’s not immediately clear how many people will be directly affected by the company’s closure. In September 2024, the biotech downsized by 37%, corresponding to about 10 employees, including its Chief Medical Officer Salim Yazji.
